London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...

Four co-authors are employees of Boston Pharmaceuticals, and one now consults for Boston Pharmaceuticals after being employed there during this study. One other co-author reported various industry ...

Rhythm Pharmaceuticals, Inc. may be ripe in a year. At that time, setmelanotide should be approved for HO in the U.S. and ...

The Boston Arts Academy Foundation closed its Building Our Future fundraising campaign, surpassing its $35 million goal, ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, July 9, to discuss these clinical data. Participants may register for the ...

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent solution for insulin. They<a class="excerpt-read-more" href=" More ...